NeuroPace Buy Rating Affirmed on Strong Financials and Strategic Growth Prospects

In a report released yesterday, Vik Chopra from Wells Fargo maintained a Buy rating on NeuroPace (NPCE – Research Report), with a price target of $17.00.

Vik Chopra has given his Buy rating due to a combination of factors including NeuroPace’s strong financial performance and strategic advancements. The company reported first-quarter revenues that surpassed expectations, prompting management to raise their revenue guidance for 2025. This positive outlook is further supported by the company’s ability to maintain its gross margin and operating expense guidance despite external challenges such as tariffs.
Additionally, the progress of the NAUTILUS study, with an expected FDA submission in the second half of 2025, adds to the company’s growth potential. NeuroPace’s focus on increasing sales of its RNS System and SEEG products is expected to drive significant revenue growth. These factors, combined with improved manufacturing efficiencies and stable cash burn, reinforce the Buy rating as the company demonstrates consistent execution and strategic foresight.

In another report released yesterday, J.P. Morgan also maintained a Buy rating on the stock with a $16.00 price target.

Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NPCE in relation to earlier this year.